Best et al. reported that LKB1 mutation in KRAS mutant lung adenocarcinoma confers a glutamate enriched phenotype in TME, and this feature was associated with CD8+T cell activation against PD-1, whereas treatment with the glutaminase inhibitor CB-839 inhibited CD8+T cell expansion and activation. The gene discussed is CD8A; the disease is lung adenocarcinoma.